|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001645,
umls-concept:C0054196,
umls-concept:C0264716,
umls-concept:C0302350,
umls-concept:C0597357,
umls-concept:C0871261,
umls-concept:C1280500,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C1882417,
umls-concept:C2911692
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2010-1-20
|
|
pubmed:abstractText |
Adrenergic activation is an important determinant of outcomes in chronic heart failure. Adrenergic activity is regulated in part by prejunctional alpha(2C)-adrenergic receptors (ARs), which exhibit genetic variation in humans. Bucindolol is a novel beta-AR blocking agent that also lowers systemic norepinephrine and thus is also a sympatholytic agent. This study investigated whether alpha(2C)-AR polymorphisms affect sympatholytic effects of bucindolol in patients with heart failure.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1941-3297
|
|
pubmed:author |
pubmed-author:AbrahamWilliam TWT,
pubmed-author:AndersonJeffrey LJL,
pubmed-author:BristowMichael RMR,
pubmed-author:CarlquistJohn FJF,
pubmed-author:DavisGordon WGW,
pubmed-author:Krause-SteinraufHeidiH,
pubmed-author:KrishnanVaishaliV,
pubmed-author:LavoriPhillip WPW,
pubmed-author:LazzeroniLaura CLC,
pubmed-author:LiggettStephen BSB,
pubmed-author:LowesBrian DBD,
pubmed-author:MurphyGuinevere AGA,
pubmed-author:PortJ DavidJD,
pubmed-author:RobertsonAlastair DAD,
pubmed-author:Thaneemit-ChenSuraiS
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
3
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
21-8
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:19880803-Adrenergic beta-Antagonists,
pubmed-meshheading:19880803-Aged,
pubmed-meshheading:19880803-Aged, 80 and over,
pubmed-meshheading:19880803-Female,
pubmed-meshheading:19880803-Heart Failure,
pubmed-meshheading:19880803-Humans,
pubmed-meshheading:19880803-Male,
pubmed-meshheading:19880803-Norepinephrine,
pubmed-meshheading:19880803-Polymorphism, Genetic,
pubmed-meshheading:19880803-Propanolamines,
pubmed-meshheading:19880803-Receptors, Adrenergic, alpha-2
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
An alpha2C-adrenergic receptor polymorphism alters the norepinephrine-lowering effects and therapeutic response of the beta-blocker bucindolol in chronic heart failure.
|
|
pubmed:affiliation |
University of Colorado Health Sciences Center, Aurora, CO 80045, USA. michael.bristow@ucdenver.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, Non-P.H.S.,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
